Two Companies To Watch From Pennytobuck.com - Pwrm.ob, Ford
Forward Industries Inc
Forward Industries Inc. (NASDAQ:FORD) (the Company or Forward) and LaGrange Capital Partners recently reported that LaGrange founder and general partner Frank LaGrange Grange Johnson will assume the role of Chairman of the Board of Forward Industries, a technology solutions provider that designs, markets and distributes carrying cases and accessories for the handheld consumer electronics and medical device industries. Additionally, Brett M. Johnson will take over as CEO.
Doug Sabra made the announcement that he is immediately stepping down as Acting Chairman and CEO. In addition, Owen King and Stephen Key are joining the Board of Directors, replacing Bruce Galloway and Michael Schiffman. Mr. Schiffman has agreed to serve as an ongoing advisor to the Company. Grange Johnson wished Sabra and the outgoing board members well and thanked them for their years of dedicated service.
Forward Industries, Inc., incorporated in 1961, designs, markets and distributes soft-sided carrying cases, bags, clips and other accessories for the handheld consumer electronic product industry, including cellular telephones and medical monitoring and diagnostic kits. Its principal customers are original equipment manufacturers (OEMs). The Company's suppliers custom manufacture its carrying cases and related products to the order of its original equipment manufacturer (OEM) customers. Forward Industries designs and markets to its customers' order soft-sided carrying cases, bags, hand straps, clips and decorative faceplates made of leather, nylon, vinyl, plastic, polyvinyl chloride (PVC) and other synthetic fabrics through its wholly owned subsidiaries, Koszegi and Forward Innovations.
**************************
Power3 Medical Products, Inc. (OTC.BB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, reported that Power3 delivered four poster presentations at the 2010 International Conference on Alzheimers Disease (ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, Power3s diagnostic test, and focused on Power3s Alzheimers disease blood serum biomarkers, test and clinical validation trials.
In preparation for commercialization, our objective at this meeting was to show how Power3s protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimers disease, said Dr. Ira L. Goldknopf, Power3s President and Chief Scientific Officer. It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3s protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs.
We are pleased that our blood tests specifically diagnose Alzheimers in patients, both pre- and post-treatment, said Helen R. Park, MS, Chief Executive Officer of Power3, and that our scientific collaborators, Dr. Marwan Sabbagh, Medical and Scientific Director of the Banner Sun Health Medical Research Institute, and Dr. Lourdes R. Bosquez, President of the Woodlands Behavioral Institute, Inc., presented along with us at the meeting in Hawaii.
We are within striking distance of realizing an Alzheimers clinical diagnostic tool which I hope will lead to a greater understanding of the disease and buoy the pace of future therapeutic interventions, added Marwan Sabbagh MD, Medical and Scientific Director of Banner Sun Health Medical Research Institute.
Power3 has filed several patent applications for its NuroPro technology that are currently pending. Power3 also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, Power3 has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. Power3 intends to publish these latest findings as well.
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimers disease, Parkinsons disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrigs disease). Power3 Medical applies proprietary methodologies to discover and identify protein biomarkers associated with diseases.
******************************************************************
For FREE Daily Stock Alerts & Updates Sign-up At: http://pennytobuck.com/signup
********************************************************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer (http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.
Crown Equity Holdings Inc. (CRWE.OB) has previously received five hundred thousand shares as compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings Inc. had received an additional amount of 2,000,000 shares of free trading stock for 60 days of media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB). Each advertising commitment has now expired.
by: Bill Pennyman
Marginalization Of A Crisis Of Traditional Tv Audio "sound" Level Updating Online Car Shopping Etiquette. New Ford Fiesta On The Road Choosing The Best Tooth Whitener That Is Affordable And Safe Take These Steps In Order To Ensure That Your Vehicle Is Functioning Properly MORVacations - Too Good to Be True? Arizona Injury Attorneys - Car Accident Attorney Should I Get Divorced In England Or Abroad? Comfortable Car seat covers Getting a Car Loan With a Bad Credit Htc Evo 4g - Its Dazzling Array Of Features Will Amaze You Why and Where to Buy Used Mahindra Cars Htc Evo 4g - Why Is Its Name Being Mentioned Everywhere?